Abbott Labs Raises 2022 Covid Testing Sales Guidance
20 Avril 2022 - 02:28PM
Dow Jones News
By Will Feuer
Abbott Laboratories raised its full-year Covid-19
testing-related sales guidance, but lowered its expectations for
annual earnings.
The Abbott Park, Ill.-based medical-products company said it now
expects about $4.5 billion in Covid-19 testing-related sales for
the year, with much of that expected to occur in the first half of
the year. In January, the company said it expected Covid-19 testing
sales of about $2.5 billion.
In 2021, the company recorded about $7.7 billion in Covid-19
testing-related sales.
Abbott lowered its full-year guidance for earnings to at least
$3.35 a share from at least $3.43 a share previously. The company
maintained adjusted earnings from continuing operations guidance of
at least $4.70 a share.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
April 20, 2022 08:13 ET (12:13 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Abbott Laboratories (NYSE:ABT)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Abbott Laboratories (NYSE:ABT)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024